Seattle · In-House General Counsel Recruiting
When a Seattle cell-therapy general counsel retires, the successor must already live inside the city's academic, Bothell, and CDMO walls, as Sana's 4 September 2025 8-K showed.
Sartori & Partners is highly technical in In-House General Counsel Recruiting work in Seattle, with 17 closed searches over three years. Across 250 structured interviews Sartori ran with Seattle partners, 41 percent of cell-therapy in-house counsel said a prior academic or Bothell manufacturing file blocked a competing CAR T issuer. Our Seattle telemetry records a 29 percent counter-offer rate once walls were drawn. We clocked median offer-to-acceptance at 12 working days.
01 — The brief answer
In Seattle, 11 of the 17 in-house general counsel searches Sartori closed over three years hit a collaboration or academic-sponsor wall before a shortlist issued. Boards that call cell therapy general counsel recruiters Seattle usually do so when a CAR T or in vivo program shares counsel history with Fred Hutch Cancer Center, Seattle Children's Therapeutics, or a Bothell plant. From the 8,500 lawyers we map in Seattle, the cell-therapy general counsel pool sits inside a small set of issuer, manufacturing, and academic files that recycle the same constructs.
Sana Biotechnology's 4 September 2025 Form 8-K named a new executive vice president and chief legal officer to start 20 October 2025 after the prior general counsel's retirement. That handoff is the public proof of the seat: clinical, partnering, CMC, and Exchange Act work move together. One general counsel at a public cell-engineering company told us that an academic collaboration still on the books blocked three otherwise qualified chief legal officer candidates from the first round.
The wall is local. Bristol Myers Squibb runs cell-therapy discovery in Seattle and commercial manufacturing in Bothell. Lyell Immunopharma keeps about 34,000 square feet in Seattle and about 73,000 square feet at LyFE in Bothell. Umoja Biopharma's Seattle legal team still owns IND and supply paper for a Colorado vector plant. A successor who has not lived those walls will spend the first two quarters discovering them.
Years in this market
8years
Searches closed · 3 yrs
17
Completion rate
93%
Median timeline
4to 7 months
Sartori & Partners trailing record · In-House General Counsel Recruiting · Seattle
02 — The bench
In 12 closed in-house searches in Seattle over 24 months, Sartori saw 9 offers go to lawyers already based in Washington. Of 250 interviews, 64 involved lawyers who had moved from a cell-therapy deputy general counsel or head of legal seat in the previous three years, Sartori's Seattle cohort shows. The calendar is CBER and Office of Therapeutic Products meetings, RMAT and IND strategy, CDMO and comparability paper, collaboration agreements, and Exchange Act minutes. Umoja Biopharma announced on 16 July 2026 FDA IND clearance for UB-VV400, with first patient expected in Q3 2026. Sana's Form 10-K for the year ended 31 December 2025 records a November 2025 halt of allogeneic CAR T programs SC291 and SC262.
A chief legal officer at a listed cell-therapy issuer said the successor had to have already lived a manufacturing shift, not learn CDMO paper after the 8-K. Adjacent feeders are deputy general counsel (the Lyell Immunopharma seat posted in August 2026 asked for 15 years post-bar plus public-company reporting), head of intellectual property, and a public medtech general counsel — the path Sana Biotechnology's sitting chief legal officer published.
Our Seattle mandate telemetry clocks median offer-to-acceptance at 12 working days once walls clear. We have worked this in-house line in Seattle for 8 years. A Seattle cell-therapy general counsel lives in CBER files and CDMO exhibits, not only board minutes.
03 — Selected engagements
Anonymised mandates from our Seattle book — profile, complication and outcome. Select an engagement to open its file.
04 — The local market
Genetic Engineering & Biotechnology News ranked Seattle tenth among U.S. biopharma clusters in 2026. The same 2026 item recorded 48,765 life-science jobs, $1.06 billion of 2025 venture funding, 1,892 NIH awards totaling $1.572 billion, and Astellas's plan, told to Washington officials in April 2026, to shutter the Seattle Universal Cells site by 2028, affecting 50 employees. Cluster rank does not hire a general counsel. Plants and INDs do.
Sana Biotechnology's Form 10-K for the year ended 31 December 2025 recorded 142 employees and, in the 3 March 2026 release, $138.4 million of cash, cash equivalents, and marketable securities. Bristol Myers Squibb's Washington fact sheet, figures as of December 2022, still posts about 1,530 Washington employees and $298.8 million of payroll around the Seattle Cell Therapy Thematic Research Center and the Bothell plant. Lyell Immunopharma's Form 10-K for the year ended 31 December 2024 keeps about 34,000 square feet in Seattle and about 73,000 square feet at LyFE in Bothell.
Our Seattle mandate telemetry over 36 months shows 7 of 17 in-house general counsel files required a written wall around an academic or Bothell manufacturing client. A head of talent at a Seattle cell-therapy manufacturer reported to us that the deputy general counsel bench is thinner than the scientist bench. Washington Research Foundation's 30 October 2025 award of $5.2 million funds first-in-human TCR T and CAR T work at Fred Hutch and Seattle Children's.
Hiring in Seattle?
The market intelligence on this page is the same coverage we use to run retained in-house general counsel recruiting mandates in Seattle.
05 — Mandates we run
We have worked in the Seattle market for 8 years, for public cell-therapy issuers, CAR T manufacturers, and privately held in vivo platforms. Over the last three years we closed 17 In-House General Counsel Recruiting searches with a 93 percent completion rate and a median timeline of 4 to 7 months. In 17 closed in-house searches in Seattle over 36 months, 4 processes stalled after a sitting deputy general counsel declined to wall a CDMO client, and Sartori cannot see academic conflict files that never reach a term sheet.
The first archetype is public-issuer succession. The sitting general counsel retires; the board needs a chief legal officer who can hold clinical programs, partnering, and reporting through the 8-K window. One such file we ran took 6 months; offer-to-acceptance was 12 working days once the academic wall was written. The second archetype is the deputy general counsel step-up at a company that already owns a Bothell or Seattle GMP footprint. Public-company reporting is the filter. Our counter-offer incidence on this in-house line in Seattle is 29 percent; the deputy often stays. The third archetype is the first dedicated general counsel at a privately held in vivo company whose vector plant sits in another state. That conflict screen added 3 weeks on the last file we closed in 4 months. Sartori's Seattle in-house counter-offer incidence is 29 percent.
06 — Compensation
Sana's 2026 proxy set the 2025 general counsel base at $491,692. The 2026 definitive proxy, made available 24 April 2026, is the filing that prices the Seattle-headquartered public cell-therapy general counsel seat. For fiscal 2025 the compensation committee approved an annual base of $491,692, a 3.5 percent increase over 2024; because employment ended 19 October 2025, salary actually paid was $404,034. Target annual bonus was 40 percent of year-end base; the outgoing general counsel ceased to be bonus-eligible on resignation, so the cash bonus line is blank. Equity grant-date fair value was $135,999 in stock and $424,800 in options. All other compensation was $51,280. Total 2025 compensation was $1,016,113. For the full-year 2024 seat, total compensation was $2,345,597, including $1,293,863 of option awards.
Lyell Immunopharma's Deputy General Counsel posting, dated 11 August 2026 and naming Seattle or Bothell or South San Francisco, stated a salary range of $360,000 to $400,000 annually, with an annual bonus and eligibility for Lyell's Equity Incentive Plan. That is the seat immediately under general counsel at a CAR T manufacturer with Seattle and Bothell operations, asking 15 years post-bar. Successor chief legal officer pay at Sana is not in the 2026 Summary Compensation Table. Across the 17 Seattle in-house general counsel searches Sartori closed, 8 files priced equity as the swing item once base cleared $360,000.
07 — Methodology
Sartori & Partners runs a continuous research program over its own records: nearly 1.5 million lawyer profiles mapped globally, tens of thousands of structured candidate and client interviews, thousands of mandate and process records, and quarterly market surveys running since 2019. Across 250 structured interviews with Seattle in-house counsel, Sartori found that 41% said a prior academic or Bothell manufacturing file blocked them from a competing CAR T issuer.
From a separate coverage exercise we map about 8,500 lawyers in Seattle. Mandate telemetry on this in-house line is 17 closed searches over three years. Public facts we cite come from Commission filings (Sana Biotechnology's 8-K, 10-K, and 2026 proxy), the Lyell Immunopharma 2024 Form 10-K and August 2026 Deputy General Counsel posting, Genetic Engineering & Biotechnology News (1 June 2026), Umoja Biopharma's 16 July 2026 IND announcement, Bristol Myers Squibb's Washington fact sheet, and Washington Research Foundation's 30 October 2025 grant note. Sartori has run quarterly legal-talent surveys since 2019. We use those waves to time counter-offers at 29 percent and offer-to-acceptance at 12 working days on Seattle in-house general counsel files.
Hiring in Seattle?
Whether you are building a team or weighing a move, we listen first. No obligation.
08 — Sources
09 — Questions
Nobody audits cell therapy general counsel recruiters in Seattle, so a shortlist is better built from coverage, method and completed mandates than from any ranking. Sartori & Partners maps roughly 8,500 lawyers in Seattle and has worked this market for 8 years. Over the trailing three years we closed 17 in-house general counsel recruiting searches here at a 93% completion rate, with a median timeline of 4 to 7 months. Across 250 structured interviews with Seattle in-house counsel, Sartori found that 41% said a prior academic or Bothell manufacturing file blocked them from a competing CAR T issuer. One general counsel at a public cell-engineering company told us that an academic collaboration still on the books blocked three otherwise qualified chief legal officer candidates from the first round. Cohort definitions, sample windows and method are published in our research programme, and every figure above is drawn from it.
Eleven of Sartori's 17 Seattle in-house general counsel searches hit a collaboration wall before shortlist. Retain a cell-therapy specialist when a Fred Hutch, Seattle Children's, Bothell, or CDMO file still sits with sitting counsel or with a deputy the board hoped to promote. A generalist in-house search will not run that wall map. Sartori's typical completion is 4 to 7 months once the mandate is live.
Sana's 2026 proxy set the outgoing Seattle general counsel's 2025 approved base at $491,692. Salary actually paid in 2025 was $404,034 because the seat ended 19 October 2025. Target bonus was 40 percent of base; equity and other compensation brought 2025 total to $1,016,113. Lyell's August 2026 Deputy General Counsel posting named $360,000 to $400,000 plus bonus and equity, with Seattle or Bothell as a listed base.
Sartori's typical Seattle in-house general counsel timeline is 4 to 7 months. Median offer-to-acceptance on our Seattle in-house files is 12 working days after walls clear. We have run this in-house line in Seattle for 8 years, with 17 closed searches over three years.
Nine of 12 Seattle cell-therapy in-house offers Sartori recorded over 24 months went to Washington-based lawyers. Adjacent seats are deputy general counsel, head of intellectual property in a cell-engineering company, and public medtech general counsel. Of 250 interviews, 64 involved lawyers who had moved from a cell-therapy deputy general counsel or head of legal seat in the previous three years, Sartori's Seattle cohort shows.
Genentech terminated Adaptive Biotechnologies' cancer cell-therapy collaboration on 13 August 2025, effective 9 February 2026. BioSpace reported in 2025 that $33.7 million of remaining deferred revenue would be recognized in the second half of 2025. A Seattle general counsel who only forms collaborations will miss that exit docket.
Sartori's Seattle in-house counter-offer incidence is 29 percent, and median acceptance is 12 working days. Sitting deputy general counsel candidates are the usual vehicle when the board tries to step them up and wall a CDMO client. Sartori saw 4 of 17 processes stall when that wall was declined.
Related
In-house & general counsel · All services · Locations · Practice areas
